Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Adenoid Cystic Carcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Bowens Disease (2)

Bowens Disease (2)

›

No biomarker	Bowens Disease	No biomarker	Bowens Disease	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2
No biomarker	Bowens Disease	No biomarker	Bowens Disease	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
MYB underexpression	Adenoid Cystic Carcinoma	MYB underexpression	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
NOTCH1 mutation	Adenoid Cystic Carcinoma	NOTCH1 mutation	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
NOTCH mutation	Adenoid Cystic Carcinoma	NOTCH mutation	Adenoid Cystic Carcinoma	AL101 Sensitive: C3 – Early Trials AL101 Sensitive : C3	AL101 Sensitive: C3 – Early Trials AL101 Sensitive : C3
NOTCH1 positive + FGFR2 mutation	Adenoid Cystic Carcinoma	NOTCH1 positive + FGFR2 mutation	Adenoid Cystic Carcinoma	lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive : C4	lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive : C4
MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8	Adenoid Cystic Carcinoma	MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8	Adenoid Cystic Carcinoma	anlotinib + eribulin mesylate Sensitive: C4 – Case Studies anlotinib + eribulin mesylate Sensitive : C4	anlotinib + eribulin mesylate Sensitive: C4 – Case Studies anlotinib + eribulin mesylate Sensitive : C4
BCOR L1524Hfs*8	Adenoid Cystic Carcinoma	BCOR L1524Hfs*8	Adenoid Cystic Carcinoma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4
BCOR F1106Tfs*5	Adenoid Cystic Carcinoma	BCOR F1106Tfs*5	Adenoid Cystic Carcinoma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4
MYB-NFIB fusion	Adenoid Cystic Carcinoma	MYB-NFIB fusion	Adenoid Cystic Carcinoma	M6620 Sensitive: D – Preclinical M6620 Sensitive : D	M6620 Sensitive: D – Preclinical M6620 Sensitive : D
PIK3CA mutation	Adenoid Cystic Carcinoma	PIK3CA mutation	Adenoid Cystic Carcinoma	PI3K inhibitor Sensitive: D – Preclinical PI3K inhibitor Sensitive : D	PI3K inhibitor Sensitive: D – Preclinical PI3K inhibitor Sensitive : D
MYB fusion + PIK3CA mutation	Adenoid Cystic Carcinoma	MYB fusion + PIK3CA mutation	Adenoid Cystic Carcinoma	PI3K inhibitor Sensitive: D – Preclinical PI3K inhibitor Sensitive : D	PI3K inhibitor Sensitive: D – Preclinical PI3K inhibitor Sensitive : D
AXL overexpression	Adenoid Cystic Carcinoma	AXL overexpression	Adenoid Cystic Carcinoma	ADCT-601 Sensitive: D – Preclinical ADCT-601 Sensitive : D	ADCT-601 Sensitive: D – Preclinical ADCT-601 Sensitive : D